eigerbioadmin

»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 136 blog entries.
19 11, 2018

Eiger to Participate in Piper Jaffray Healthcare Conference

2018-11-21T11:28:38+00:00

Eiger to Participate in Piper Jaffray Healthcare Conference PALO ALTO, Calif., November 19, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the 30th Annual Piper Jaffray Healthcare Conference on November 27 [...]

Eiger to Participate in Piper Jaffray Healthcare Conference2018-11-21T11:28:38+00:00
9 11, 2018

Eiger Bio Reports Third Quarter 2018 Financial Results

2018-11-09T14:32:39+00:00

Eiger Bio Reports Third Quarter 2018 Financial Results - HDV Phase 3 D-LIVR study start in 2018 and Progeria NDA planned in 2019 - Over $100 million in cash to advance late stage rare disease pipeline PALO ALTO, Calif., November 9, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted [...]

Eiger Bio Reports Third Quarter 2018 Financial Results2018-11-09T14:32:39+00:00
23 10, 2018

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock

2018-11-07T11:44:18+00:00

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock PALO ALTO, Calif., October 23, 2018 – Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the accelerated development and commercialization of targeted therapies for rare and ultra-rare diseases, announced today the pricing of its previously announced underwritten public offering.  The Company announced [...]

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock2018-11-07T11:44:18+00:00
22 10, 2018

Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019

2018-10-22T16:25:07+00:00

Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019 - Designation Enables Priority Review Voucher Eligibility Upon NDA Approval PALO ALTO, Calif., October 22, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies [...]

Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 20192018-10-22T16:25:07+00:00
22 10, 2018

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock

2018-10-23T10:38:36+00:00

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PALO ALTO, Calif., October 22, 2018 – Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that it has commenced an underwritten public offering of its common stock.  Eiger intends to grant the underwriters a 30-day [...]

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock2018-10-23T10:38:36+00:00
18 10, 2018

Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference

2018-10-18T17:03:58+00:00

Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference PALO ALTO, Calif., October 18, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced the Eiger management team will participate and host 1:1 investor meetings at the BTIG Biotech Conference at the Langham Hotel in New [...]

Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference2018-10-18T17:03:58+00:00
17 10, 2018

Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection

2018-10-17T20:58:12+00:00

Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection Lambda Antiviral Activity Demonstrated in HDV Infection Currently Dosing Lambda in Combination with Lonafarnib in HDV Infection PALO ALTO, Calif., October 17, 2018 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced positive [...]

Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection2018-10-17T20:58:12+00:00
16 10, 2018

Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint

2018-10-16T21:16:17+00:00

Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint PALO ALTO, Calif., October 16, 2018 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced Phase 2 ULTRA study results in primary and secondary [...]

Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint2018-10-16T21:16:17+00:00
16 10, 2018

Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)

2018-10-16T21:09:57+00:00

Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH) Primary and Secondary Endpoints Achieved with Statistical SignificanceAvexitide Treatment Reduces Hypoglycemia and Hyperinsulinism PALO ALTO, Calif., October 16, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today [...]

Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)2018-10-16T21:09:57+00:00
25 09, 2018

Eiger BioPharmaceuticals to Participate in Investor Conferences

2018-09-25T13:50:24+00:00

Eiger BioPharmaceuticals to Participate in Investor Conferences PALO ALTO, Calif., September 25, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present at two investor conferences in October in New York City. Cantor Fitzgerald 4th [...]

Eiger BioPharmaceuticals to Participate in Investor Conferences2018-09-25T13:50:24+00:00